GCP
CNTX icon

GSA Capital Partners’s Context Therapeutics CNTX Stock Holding History

GSA Capital Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,122
Closed -$28K – 1714
2024
Q4 		$28K Buy
+27,122
New +$46.9K ﹤0.01% 1550

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

GSA Capital Partners's CNTX Position: Q1 2025 in Review

GSA Capital Partners sold out of Context Therapeutics (CNTX) in Q1 2025, closing a stake of 27,122 shares — an estimated $28K sold.

GSA Capital Partners first reported a position in CNTX in Q4 2024 and held it in 1 quarter. The position peaked at $28K in Q4 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q1 2025.

  • GSA Capital Partners reported no remaining Context Therapeutics position as of Q1 2025 after selling out during the quarter.
  • GSA Capital Partners sold 27,122 Context Therapeutics shares in Q1 2025, an estimated $28K.
  • GSA Capital Partners first reported a position in Context Therapeutics in Q4 2024 and held it in 1 quarter.
  • GSA Capital Partners's Context Therapeutics position peaked at $28K in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.